March 12, 2020 at 4:01 PM EDT Phase 2 MARINA, MISSION and PRESIDIO trials with KZR-616 are progressing Additional data from the ongoing Phase 1b portion of the MISSION study to be presented during various medical conferences throughout the course of 2020 KZR-261, a first-in-class protein secretion inhibitor, is currently undergoing… Read More..

Conference Call to be held Wednesday, March 11, 2020 at 5:00 pm EDT Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full year ended December 31,… Read More..

New York, NY, March 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Ohanae, (https://www.ohanae.com/), an institutional grade asset tokenization platform creating a new opportunity for capital market innovation, today announced the introduction of the Ohanae Asset Tokenization Platform, powered by its foundational stablecoin, the Ohana Coin. Commenting on the launch,… Read More..